JP2019524690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524690A5 JP2019524690A5 JP2018568951A JP2018568951A JP2019524690A5 JP 2019524690 A5 JP2019524690 A5 JP 2019524690A5 JP 2018568951 A JP2018568951 A JP 2018568951A JP 2018568951 A JP2018568951 A JP 2018568951A JP 2019524690 A5 JP2019524690 A5 JP 2019524690A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- patient
- niraparib
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212103A JP7900914B2 (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US62/356,461 | 2016-06-29 | ||
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US62/402,427 | 2016-09-30 | ||
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| US62/470,141 | 2017-03-10 | ||
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212103A Division JP7900914B2 (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524690A JP2019524690A (ja) | 2019-09-05 |
| JP2019524690A5 true JP2019524690A5 (enExample) | 2020-08-13 |
| JP7083760B2 JP7083760B2 (ja) | 2022-06-13 |
Family
ID=60787744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568951A Active JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
| JP2021212103A Active JP7900914B2 (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212103A Active JP7900914B2 (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US12383542B2 (enExample) |
| EP (2) | EP4302835A3 (enExample) |
| JP (2) | JP7083760B2 (enExample) |
| KR (2) | KR102510996B1 (enExample) |
| CN (1) | CN109640992A (enExample) |
| AU (1) | AU2017290244B2 (enExample) |
| BR (1) | BR112018077492A2 (enExample) |
| CA (1) | CA3029671C (enExample) |
| DK (1) | DK3478286T3 (enExample) |
| ES (1) | ES2969816T3 (enExample) |
| FI (1) | FI3478286T3 (enExample) |
| HR (1) | HRP20240136T1 (enExample) |
| HU (1) | HUE064978T2 (enExample) |
| IL (1) | IL263925B2 (enExample) |
| LT (1) | LT3478286T (enExample) |
| MX (1) | MX394062B (enExample) |
| NZ (1) | NZ749413A (enExample) |
| PL (1) | PL3478286T3 (enExample) |
| PT (1) | PT3478286T (enExample) |
| RS (1) | RS65180B1 (enExample) |
| SG (1) | SG11201811564QA (enExample) |
| SI (1) | SI3478286T1 (enExample) |
| SM (1) | SMT202400105T1 (enExample) |
| WO (1) | WO2018005818A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| MA50677A (fr) | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) * | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| ES3069978T3 (en) | 2018-10-17 | 2026-06-11 | Tempus Ai Inc | Data based cancer research and treatment systems and methods |
| US10957433B2 (en) | 2018-12-03 | 2021-03-23 | Tempus Labs, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| US11705226B2 (en) | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| WO2021011609A1 (en) * | 2019-07-15 | 2021-01-21 | Tesaro, Inc. | Methods of treating ovarian, fallopian tube and peritoneal cancer |
| JP7638963B2 (ja) * | 2019-08-22 | 2025-03-04 | テンパス・エーアイ・インコーポレイテッド | 高次元時系列薬剤データからの教師なし学習および治療ラインの予測 |
| WO2021138215A1 (en) * | 2019-12-31 | 2021-07-08 | Kinnate Biopharma Inc. | Treatment of cancer with cdk12/13 inhibitors |
| WO2021146213A1 (en) * | 2020-01-13 | 2021-07-22 | Gradalis, Inc. | Methods for treating cancers using gm-csf encoding polynucleotide and additional agents |
| JP2023524794A (ja) * | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| KR102858757B1 (ko) | 2022-01-25 | 2025-09-10 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
| CN121866063A (zh) * | 2023-09-19 | 2026-04-14 | 上海瑛派药业有限公司 | Parp抑制剂在卵巢癌维持治疗中的应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| MX2010004028A (es) | 2007-10-17 | 2010-04-30 | Kudos Pharm Ltd | 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona. |
| AU2008321382A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US8500933B2 (en) | 2007-12-14 | 2013-08-06 | Guardian Industries Corp. | Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| JP2013503173A (ja) | 2009-08-26 | 2013-01-31 | セファロン、インク． | 多環系化合物の新規形態 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| WO2014085698A1 (en) | 2012-11-28 | 2014-06-05 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex |
| DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| MA39740A (fr) | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| JP6648040B2 (ja) * | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
| WO2016033103A1 (en) | 2014-08-25 | 2016-03-03 | Creatv Microtech, Inc. | Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| IL293821A (en) | 2015-07-02 | 2022-08-01 | Acerta Pharma Bv | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| CN108701172A (zh) | 2016-02-12 | 2018-10-23 | 南托米克斯有限责任公司 | 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点 |
| US11154538B2 (en) * | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432055A (zh) | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TWI791519B (zh) | 2017-04-27 | 2023-02-11 | 美商提薩羅有限公司 | 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| TW201929902A (zh) | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
| WO2021011609A1 (en) | 2019-07-15 | 2021-01-21 | Tesaro, Inc. | Methods of treating ovarian, fallopian tube and peritoneal cancer |
| US20220395439A1 (en) | 2019-11-22 | 2022-12-15 | Medipool Co., Ltd. | Antibacterial deodorant composition and production method therefor |
-
2017
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en not_active Ceased
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt not_active Application Discontinuation
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active Active
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 MX MX2018016193A patent/MX394062B/es unknown
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Ceased
- 2017-06-29 SM SM20240105T patent/SMT202400105T1/it unknown
-
2018
- 2018-05-22 US US15/986,536 patent/US12383542B2/en active Active
-
2021
- 2021-12-27 JP JP2021212103A patent/JP7900914B2/ja active Active
-
2022
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US12527780B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3478286T3 (fi) | Menetelmiä munasarjasyövän hoitamiseksi | |
| JP2022031478A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| JP2014530874A5 (enExample) | ||
| JP2017226708A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2016528162A5 (enExample) | ||
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| JP2016536286A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| MA46709A (fr) | Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale | |
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2019505529A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016513703A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer |